Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,903 signal articles · 91 in last 24h · 149,376 total before filter · latest 54m ago
91last 24h
964last 7d
108● bullish (7d)
117● bearish (7d)
212publishers
AllMacro361Earnings106M&A110Regulatory13Product16Analyst6
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Reasons U is Risky and 1 Stock to Buy Instead
StockStory9d agobullish
3 Reasons U is Risky and 1 Stock to Buy Instead

Unity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 110%, reaching $42.03 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

3 Reasons to Avoid C and 1 Stock to Buy Instead
StockStory9d agobullish
3 Reasons to Avoid C and 1 Stock to Buy Instead

Over the past six months, Citigroup has been a great trade, beating the S&P 500 by 14.1%. Its stock price has climbed to $138.48, representing a healthy 26.8% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales
Insider Monkey9d agobullish
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales

On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead’s HIV medication for the […]

Does Arrow Electronics Still Buy Back Enough Stock To Matter?
Trefis9d agobullish
Does Arrow Electronics Still Buy Back Enough Stock To Matter?

Arrow Electronics (ARW) stock has gained about 50% over the past six months and then stopped. It has slipped 1.0% over the past three months and trades roughly 9% below its 52-week high. Underneath the run is a machine that pays owners whether or not the price moves: a shrinking share count. It is shrinking more slowly now, and that changes what you are buying.

2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead
StockStory9d agobullish
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead

Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.